PCM
BSX icon

Prelude Capital Management’s Boston Scientific BSX Stock Holding History

Prelude Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-40,000
Closed -$1.4M – 1851
2020
Q2 		$1.4M Buy
+40,000
New +$1.44M 0.08% 238
2013
Q4 		– Sell
-27,100
Closed -$318K – 1631
2013
Q3 		$318K Buy
+27,100
New +$293K 0.05% 403

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prelude Capital Management's BSX Position: Q1 2026 in Review

Prelude Capital Management reduced its Boston Scientific (BSX) stake by 23% in Q1 2026, selling an estimated $122K and leaving 5,253 shares worth $330K. The position accounts for 0.03% of the portfolio, ranked #672.

Prelude Capital Management first reported a position in BSX in Q2 2013 and has held it in 30 quarters since. The position peaked at $4.06M in Q3 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Prelude Capital Management held 5,253 shares of Boston Scientific worth $330K as of Q1 2026.
  • Prelude Capital Management sold 1,527 Boston Scientific shares in Q1 2026, an estimated $122K.
  • Boston Scientific made up 0.03% of Prelude Capital Management's portfolio in Q1 2026, its #672 holding.
  • Prelude Capital Management first reported a position in Boston Scientific in Q2 2013 and has held it in 30 quarters since.
  • Prelude Capital Management's Boston Scientific position peaked at $4.06M in Q3 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.